Drug intelligence / Profile preview

18FAl-NOTA-HER2 Affibody

Development stage: Unknown
Lead developer: Peking University Cancer Hospital & Institute
Modality: Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

A radiopharmaceutical imaging agent consisting of a small engineered protein (affibody) that specifically binds to the human epidermal growth factor receptor 2 (HER2). The affibody is conjugated with NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) as a chelator and labeled with aluminum fluoride-18 (^18F), enabling positron emission tomography (PET) imaging. This agent is designed for noninvasive detection and quantification of HER2 expression in tumors—primarily breast cancer—allowing for improved staging and assessment of HER2-positive lesions. The mechanism involves high-affinity binding to the extracellular domain of HER2 on tumor cells; after intravenous administration and PET/CT scanning at defined intervals post-injection, it provides high-contrast images correlating with HER2 status[3][4][5]. Developed primarily for diagnostic purposes rather than therapy.

Other names: 18F-labeled HER2 affibodyAl18F-NOTA-HER2-BCHAl-18F-NOTA-HER2-BCHAl 18F-NOTA-HER2-BCH18FAl-NOTA-MAL-cys-M0-ZHER2:342

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on 18FAl-NOTA-HER2 Affibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18FAl-NOTA-HER2 Affibody.

Explore the full profile